Document Detail


Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway.
MedLine Citation:
PMID:  11422739     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) have been shown to lower hematocrit and erythropoietin (EPO), but a direct link between angiotensin II (Ang II) and EPO in humans has not been shown. METHODS: Placebo or Ang II was infused for six hours in nine healthy male volunteers with and without blockade of the Ang II subtype 1 receptor (AT1R). EPO concentrations were measured 3, 6, 12, and 24 hours after the start of the infusion. RESULTS: Ang II raised the mean arterial pressure by about 20 mm Hg. Consistent with the known diurnal variation, EPO levels rose significantly (P < or = 0.02) during the day in all groups. During Ang II infusion, EPO levels rose to significantly higher levels after 6 and 12 hours compared with placebo [9.9 +/- 3.5 vs. 7.2 +/- 3.1 mU/mL (3 h, P = NS); 16.9 +/- 4.5 vs. 8.8 +/- 3.7 mU/mL (6 h, P = 0.01); 17.0 +/- 8.6 vs. 11.1 +/- 4.7 mU/mL (12 h, P = 0.01)] and returned to baseline after 24 hours (7.9 +/- 3.8 vs. 10.6 +/- 8.6 mU/mL, P = NS). With AT1R blockade, blood pressure remained normal during Ang II infusion, and EPO levels were never significantly different from placebo [6.8 +/- 4.8, 10.5 +/- 5.6, 13.1 +/- 9.0, and 12.4 +/- 10.1 mU/mL at 3, 6, 12, and 24 h after infusion, respectively, P = NS]. CONCLUSIONS: Ang II increases EPO levels in humans. This increase requires the participation of AT1R.
Authors:
J Gossmann; R Burkhardt; S Harder; T Lenz; A Sedlmeyer; U Klinkhardt; H Geiger; E H Scheuermann
Related Documents :
1974739 - Angiotensin ii and alpha-agonist. i. responses of ovine fetoplacental vasculature.
10500039 - 1166 a/c polymorphism of the angiotensin ii type 1 receptor gene and the response to sh...
3022609 - Total peripheral resistance during cardiac tamponade: adrenergic and angiotensin roles.
6342909 - Hypokalaemia stimulates prostacyclin synthesis in the rat.
12877769 - Intravenous angiotensin ii does not affect dynamic baroreflex characteristics of the ne...
9459229 - Treating anesthesia-induced hypotension by angiotensin ii in patients chronically treat...
2766589 - Separation of afterload reduction and a direct beneficial cardiac effect of nifedipine ...
23375309 - Factors affecting intraoperative changes in regional cerebral oxygen saturation in pati...
11040229 - Transforming growth factor beta in hypertensives with cardiorenal damage.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Kidney international     Volume:  60     ISSN:  0085-2538     ISO Abbreviation:  Kidney Int.     Publication Date:  2001 Jul 
Date Detail:
Created Date:  2001-06-25     Completed Date:  2001-08-30     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0323470     Medline TA:  Kidney Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  83-6     Citation Subset:  IM    
Affiliation:
Funktionsbereich Nephrologie, Medizinische Klinik IV, Zentrum der Inneren Medizin, and Abteilung für klinische Pharmakologie, Zentrum der Pharmakologie, J.W. Goethe-Universität, Frankfurt am Main, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Angiotensin II / pharmacology*
Blood Pressure / drug effects
Erythropoietin / blood*
Humans
Male
Osmolar Concentration
Receptor, Angiotensin, Type 1
Receptor, Angiotensin, Type 2
Receptors, Angiotensin / physiology*
Reference Values
Time Factors
Chemical
Reg. No./Substance:
0/Receptor, Angiotensin, Type 1; 0/Receptor, Angiotensin, Type 2; 0/Receptors, Angiotensin; 11096-26-7/Erythropoietin; 11128-99-7/Angiotensin II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxa...
Next Document:  Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats.